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stroke, and/or peripheral artery disease. Multiple logistic regression
analysis was performed to investigate the possible risk factors for
atherosclerosis.
From 2011 to 2012, 3658 SLE patients were enrolled. Of these, 374
(10.9%) patients suffered at least a CV event. In 269 (7.4%) patients, the
CV events occurred after SLE diagnosis (86.2% women, median [inter-
quartile range] age 54.9 years [43.2–66.1], and SLE duration of 212.0
months [120.8–289.0]). Strokes (5.7%)were themost frequent CVevent,
followed by ischemic heart disease (3.8%) and peripheral artery disease
(2.2%). Multivariate analysis identified age (odds ratio [95% confidence
interval], 1.03 [1.02–1.04]), hypertension (1.71 [1.20–2.44]), smoking
(1.48 [1.06–2.07]), diabetes (2.2 [1.32–3.74]), dyslipidemia (2.18 [1.54–
3.09]), neurolupus (2.42 [1.56–3.75]), valvulopathy (2.44 [1.34–4.26]),
serositis (1.54 [1.09–2.18]), antiphospholipid antibodies (1.57 [1.13–
2.17]), low complement (1.81 [1.12–2.93]), and azathioprine (1.47
[1.04–2.07]) as risk factors for CV events.
We have confirmed that SLE patients suffer a high prevalence of
premature CV disease. Both traditional and nontraditional risk factors
contribute to this higher prevalence. Although it needs to be verified with
future studies, our study also shows—for the first time—an association
between diabetes and CV events in SLE patients.
(Medicine 94(29):e1183)
Abbreviations: ACR = American College of Rheumatology,
BILAG = British Isles Lupus Assessment Group, CI = confidence
interval, CV = cardiovascular, CVD = cardiovascular disease, HR =
hazard ratio, LDL = low-density lipoprotein, LUMINA = lupus in
minorities: nature versus nurture, NSAID = snonsteroidal anti-
inflammatory drugs, SD = standard deviation, SDI = systemic lupus
erythematosus damage index, SELENA-SLEDAI = Safety of
Estrogens in Lupus Erythematosus National Assessment-Systemic
Lupus Erythematosus Disease Activity Index, SLE = systemic
lupus erythematosus, SLEDAI = Systemic Lupus Erythematosus
Disease Activity Index, SLICC = Systemic Lupus International
Collaborating Clinics
INTRODUCTION
T he 10-year survival rate of systemic lupus erythematosus(SLE) patients has significantly improved during the last
half century, standing at 92%.1 This improved prognosis stems
from advances in the early recognition of milder cases and an
improvement in general medical care (eg, antihypertensive,
antibiotic, and immunosuppressive drugs, hemodialysis, trans-
plantation, and others). However, long-term survival rates
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leveled off in the 1980s and since that time, 20-year survival
ranges only 44% to 84%.2 Lupus patients have a risk of
coronary artery disease that is 2 to 10 times that of the general
population, with a greater increase in relative risk generally
observed in younger patient groups.3 This reflects the fact that
lupus patients have a higher risk of accelerated atherosclerosis,
comparable to that of diabetes patients.4 Although it is unclear
why patients with SLE are at a greater risk of accelerated
atherosclerosis, both traditional and nontraditional risk factors
certainly contribute to this.
Lupus patients have a higher burden of traditional risk
factors compared with the general population.5 However, after
controlling for traditional risk factors, individuals with SLE are
at increased risk for cardiovascular disease (CVD).6,7 Measure-
ments of the incidence and prevalence of cardiovascular (CV)
events may fluctuate because of differences between studies
(eg, sample size, different populations, design, or inadequate
adjustment for potential confounding factors); a decreasing
trend in the risk might even be occurring.6–9 This trend may
be related to a better control of lupus activity and other SLE-
associated risk factors for atherosclerosis such as glucocorti-
coids, oxidative stress, adipokines, and others.10
The risk of CV events in SLE is difficult to study given that
despite the increased relative risk of CV events in this popu-
lation, the absolute number of events per year in any given
cohort is relatively small. Therefore, patient registries and
multicentric/multiethnic cohorts are tools particularly useful
for evaluating events that are relatively infrequent in chronic
diseases.11–13
The aims of this study were to estimate the frequency of
CV events in a large cohort of patients with SLE from Spain and
investigate the main traditional and SLE-associated risk factors
for atherosclerosis.
PATIENTS AND METHODS
RELESSER Registry
The RELESSER Registry is a nationwide multicenter,
hospital-based registry designed by the Systemic Autoimmune
Diseases Working Group of the Spanish Society of Rheumatol-
ogy. The study has 2 parts: an initial cross-sectional phase
(RELESSER-TRANS) and a further prospective cohort study
(RELESSER-PROS) that is currently ongoing. The study
included patients from45 rheumatology university centers spread
across Spain with substantial experience in the management of
SLE. The Research Unit of the Spanish Society of Rheumatology
was the coordinating center, providing expert methodological
support at all stages of the project and carrying out study
monitoring and inconsistency identification and resolution.
Written commitment was obtained from all investigators
prior to participation. The study was approved by the Ethics
Committee at Dr Negrı´n University Hospital, Gran Canaria,
Spain, and then by the institutional research review boards at all
participating centers. Patients signed their consent forms upon
entry in RELESSER-PROS. The study was conducted in
accordance with the Helsinki Declaration.
Study Design
RELESSER-TRANS is a cross-sectional, multicenter,
nationwide study, and includes baseline cumulative data for
every patient. A full description of the methodological issues
Ferna´ndez-Nebro et alhas been published in detail elsewhere.14 Using data from
RELESSER-TRANS, we assessed the prevalence of, and risk
factors for, CV events among SLE patients.
2 | www.md-journal.comPatients
Unselected consecutive adult patients with SLE, classified
according to the American College of Rheumatology (ACR)
1997 criteria,15 were enrolled. All patients had been attended
upon and followed at Spanish rheumatology departments.
Patients were widely and homogeneously distributed across
the country to avoid selection bias. The first patient was enrolled
in October 2011 and the last in August 2012.
Data Collection
A specific protocol was designed to collect the study
variables along with their operational definitions. The investi-
gators were trained before beginning data collection from
clinical reporting to avoiding information bias. A website for
data entry was developed and implemented (RELESSER data-
base website) to collect all information. After closing the
databases, queries for missing or inconsistent data were sent
to the investigators for additions and corrections. Ultimately, the
percentage of missing data was <5% in 92% of the variables
collected.
Definitions of Variables
Data recorded included demographic, clinical, laboratory,
and treatment information. Clinical variables included comor-
bidities (including the Charlson comorbidity index),16 disease
onset (time at which a patient met 4 ACR SLE criteria), disease
duration (from diagnosis to the last visit or until death, if
applicable), follow-up duration (from the first visit in the
rheumatology center to the last visit or until death, if
applicable), cumulative ACR criteria, Safety of Estrogens in
Lupus Erythematosus National Assessment Systemic Lupus
Erythematosus Disease Activity (SELENA-SLEDAI) descrip-
tors17 and the British Isles Lupus Assessment Group (BILAG)
2004 activity18 descriptors, Sydney criteria for antiphospholipid
syndrome,19 hospitalizations (and causes), current or past drug
treatments and reasons for interrupting them, and nonpharma-
cological treatments and death (and causes). SELENA-SLE-
DAI,17 Systemic Lupus International Collaborating Clinics
(SLICC)/ACR Damage Index (DI),20 and Katz severity index21
were all retrospectively measured at the last visit (or at death, if
applicable).
Comorbidities by patient included, among others, smoking
status, diabetes (previous diagnosis or2 fasting serum glucose
levels 126mg/dL and/or antidiabetic drugs), dyslipidemia
(total cholesterol 240mg/dL and/or low-density lipoprotein
>130mg/dL and/or triglycerides 160mg/dL and/or intake of
lipid-lowering drugs), hypertension (systolic blood pressure
140mm Hg and/or a diastolic blood pressure 90mm Hg
on 2 occasions and/or intake of antihypertensive drugs),
peripheral artery disease, ischemic heart disease, heart failure
(clinic diagnosis and/or on chest radiography), thromboembolic
disease, and/or a cerebral vascular accident.
By consensus of the RELESSER Scientific Committee of
RELESSER, refractory disease was defined by at least 1 of the
following: failure to respond to cyclophosphamide; failure of
2 immunosuppressive agents other than cyclophosphamide
(ie, methotrexate, azathioprine, mycophenolatemofetil/myco-
phenolic acid, or leflunomide); need for rituximab adminis-
tration; or splenectomy.
Medicine  Volume 94, Number 29, July 2015Outcome Variable
ACVevent (coronary and noncoronary) was defined as the
presence of at least 1 of following: ischemic heart disease,
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including myocardial infarction and/or angina pectoris based on
clinical diagnosis and/or ischemic changes in the electrocardio-
gram and/or specific changes in cardiac enzymes and/or typical
findings in a coronary angiography; cerebral vascular accident
based on a unequivocal previous diagnosis or on the presence of
clinical manifestations and/or supported by an imaging pro-
cedure (ie, computed tomography angiography or magnetic
resonance angiography); and peripheral artery disease sup-
ported on a well-established prior diagnosis or by the presence
of clinical manifestations confirmed by an imaging procedure.
In patients with multiple events, we counted up to 3 events/
patient for myocardial infarction and for established cerebro-
vascular events. For the remaining events, we counted only the
first that occurred since the SLE diagnosis was made. Patients
with CV events that occurred before a diagnosis of SLE were
excluded from the analyses.
Statistical Analysis
Data are presented as means (standard deviation [SD]),
medians (interquartile range), or totals with percentages. Base-
line characteristics were compared between groups using the x2
test, the Student t test (Fisher exact test when necessary), or the
Mann–Whitney U test.
Patient characteristics at onset of SLE, cumulative
parameters (comorbidities, treatment with glucocorticoids,
immunosuppressive drugs, and DI), and SLEDAI at last visit
were taken into account as possible risk factors in a bivariate
analysis. The Kruskal–Wallis test was used for comparing
variables according to the location of the CV events (cerebro-
vascular, noncerebrovascular, or both).
Multiple logistic regression analysis with forward stepwise
selection (Wald) was performed to study the association of
possible risk factors with the presence of CV events that had
occurred since SLEdiagnosis. Factors included in themodelwere
those that were statistically significant in the bivariate analysis.
Multicollinearity of independent variables was checked using
Pearson correlation coefficient. If the r-coefficient was>0.4, we
entered the variables separately in the models, in order to see if
Medicine  Volume 94, Number 29, July 2015any change either in associationswith the dependent variable or in
the explaining value of the model had occurred. Finally, age, sex,
disease duration, hypertension, dyslipidemia, smoking, diabetes
TABLE 1. Demographic Characteristics of 269 Patients With Car
Variables
Sex: male, n (%)
Ethnicity
Caucasian (European ancestry), n (%)
Amerindian Caucasians, n (%)
Black Africans, n (%)
Asians, n (%)
Other ancestry, n (%)
Age at protocol, median (IQR), y
Age at disease onset, median (IQR), y
Age at disease diagnosis, median (IQR), y
Age at first cardiovascular event (after SLE diagnosis), mean (SD), y
Disease duration (from last visit to onset SLE), median (IQR), mo
IQR¼ interquartile range, SD¼ standard deviation, SLE¼ systemic lupu
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.mellitus, serositis, renal disorder, neurological disorder, valvular
dysfunction, Raynaud phenomenon, anti-double-stranded
(dsDNA), low complement, antiphospholipid antibody positive,
nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials,
glucocorticoids, methotrexate, and azathioprine were entered in
the logistic regression models to identify those factors predictive
of CV events.
Two-tailed tests and a 5% significance level were used in
all analyses. The analysis was performed with the statistical
package SPSS 22.0 for MAC OS X (IBM Corp, Armonk, NY).
RESULTS
Of the 3658 eligible SLE patients enrolled in RELESSER-
TRANS, 3649 (99.7%) had sufficient CV event information
available. As it is shown in Table 1, most of the patients with CV
events since their SLE diagnosis were White women in middle
age with long-standing disease. When the percentage by dec-
ades was analyzed, we found that the frequency of immigrants
from Hispanic America with CVD increased from 1996 to
present day compared with the decades 1975 to 1985 and
1986 to 1995 (P< 0.001).
CV Events
Three hundred seventy-four (10.9%) patients suffered 448
CV events during their lifetime. Of these, 73 patients had CV
events prior to SLE diagnosis, 32 patients had missing data at the
dateof the event, and269patients (7.4%[95%confidence interval,
CI, 6.6–8.3]) suffered 318 CV events after SLE diagnosis.
The average (SD) age at the first CV event since SLE
diagnosis was 48.6 (17.1) years and the event occurred after a
median disease duration of 10.4 years following diagnosis of SLE.
As Table 2 shows, strokes were the most frequent CV
events after SLE diagnosis (5.7% [95% CI, 5.0–6.5]), followed
by ischemic heart disease (3.8% [95% CI, 3.2–4.4]). One-and-
a-half percent (5/318) of all events were fatal.
Factors Related to CV Events Since
Cardiovascular Events in Systemic Lupus ErythematosusDiagnosis of SLE
Table 3 shows the characteristics of 269 SLE patients who
had CV events compared with all other patients.
diovascular Events That Occurred After Diagnosis of SLE
Patients With Cardiovascular Events Since
SLE Diagnosis (N¼ 269)
37 (13.8)
256 (97.3)
5 (1.9)
0
2 (0.8)
0
54.9 (43.2–66.1)
34.6 (23.6–46.7)
37.3 (25.3–49.3)
48.6 (17.1)
212.0 (120.8–289.0)
s erythematosus.
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TABLE 2. Frequencies of Clinical Cardiovascular Events in
RELESSER-TRANS Patients That Occurred After Systemic Lupus
Erythematosus Diagnosis
Variables
Patients,
N (%)
No. of
Events
Ischemic heart disease 137 (3.8) —
Angina or bypass 69 (1.9) 69
Myocardial infarction 71 (1.9) 78
1 event 65 (1.8) 65
2 events 5 (0.1) 10
3 events 1 (0.0) 3
Cerebral vascular accident 208 (5.7) 213
1 event 155 (4.2) 155
2 events 20 (0.5) 40
3 events 6 (0.2) 18
Peripheral artery disease 79 (2.2) —
Vascular death 53 (1.5) —
Cardiovascular death 29 (0.8)
Cerebrovascular death 15 (0.4)
Thromboembolic 3 (0.1)
Other 6 (0.2)
Ferna´ndez-Nebro et alDemographic Factors
CV events were associated with male sex, older age at the
last visit or at death, and longer disease duration in the uni-
variate analysis (Table 3). The relatively high frequency of CV
events noted in Caucasians was because of differences in age,
follow-up time, and sex ratio.
The SLE patients who suffered only strokes were younger
(46.2 [36.0, 60.7] vs 60.5 [52.0, 73.8] vs 59.5 [47.6, 63.3] years)
and diagnosed earlier (30.3 [21.2, 43.4] vs 43.7 [31.5, 58.8] vs.
41.0 [24.9, 51.0] years) than those who suffered either non-
cerebrovascular events or vascular events in both areas
(P< 0.001, for both comparisons).
Traditional CV Risk Factors
In the univariate analysis, an association was observed
between CV events and any history of smoking, diabetes, hyper-
tension, dyslipidemia, and postmenopausal status (Table 3).
SLE-Related Risk Factors
CV events were associated with certain SLE-related fac-
tors or their comorbidities. The relative frequency of CV events
was higher in SLE patients with high SDI, Charlson index, and
Katz index at the last evaluation. Similarly, SLE patients with
either neuropsychiatric, renal, or serositis involvement, valvu-
lopathy (defined by both BILAG and SLICC/ACR DI criteria),
Raynaud phenomenon, and those with antiphospholipid syn-
drome had a higher frequency of CV event (Table 3). The
presence of either anti-dsDNA, antiphospholipid antibodies (ie,
lupus anticoagulant and/or anticardiolipin antibodies and/or
anti-B2-glycoprotein antibodies according to the revised Sidney
laboratory criteria) or low serum complement was associated
with CV events as well.
By contrast, SELENA-SLEDAI index at the last visit, a
history of mucocutaneous manifestations (ie, malar rash, dis-
coid rash, photosensitivity, or oral ulcers), arthritis, hematologic
manifestations, or sicca syndrome were not associated with CV
4 | www.md-journal.comevents. The presence of either the positivity of anti-Sm, anti-Ro,
anti-La, or anti-RNP antibodies was not associated with the
occurrence of CV events.
The SLE patients who suffered only strokes had lower
relative frequency of smoking (37.7% vs 52.7% vs 76.2%;
P¼ 0.047), dyslipidemia (52.7% vs 66.7% vs 71.4%;
P¼ 0.002), and diabetes mellitus (6.2% vs 24.3% vs 27.3%;
P< 0.001) than those who had either noncerebrovascular events
or vascular events in both the areas. The presence of valvular
dysfunction was not associated with stroke.
Treatment-Related Risk Factors
The univariate analysis showed that the frequency of CV
events was higher in patients treated with any dose of gluco-
corticoid in the past or at the last visit, a high dose of gluco-
corticoids at the last visit, immunosuppressives (at any time or
at some stage/point), statins, antiplatelets, or oral anticoagulant
drugs. The patients who were refractory to standard therapy
were also at higher risk of CV events. However, treatment with
antimalarial drugs or NSAIDs was associated with a lower
frequency of CV events.
Multivariable Analyses
Table 4 shows the variables that were included in the
multivariate models to determine which were independently
associated with CV events since SLE diagnosis. As shown,
there was a strong association between CV events and age, high
blood pressure, smoking, dyslipidemia, diabetes mellitus, ser-
ositis, low complement, neuropsychiatric lupus, valvular dys-
function (SLICC/ACR DI definition), antiphospholipid
antibodies, and azathioprine.
After adjusting the multivariate models, both antimalarial
drugs and NSAIDs were not associated with lower frequencies
of CV events. There was no association with sex, lupus nephri-
tis, anti-dsDNA antibodies, glucocorticoids, or methotrexate.
DISCUSSION
We have studied the prevalence of CV events in a large
nationwide cohort of patients with SLE from Spain. This cohort
was mainly composed of patients of European ancestry.
Although the proportion of Amerindian patients from Hispanic
America has increased over the past 15 years, its possible
influence in the cohort is still limited in comparison with the
multiethnic cohorts.13,22,23
The overall prevalence of CV events in our cohort was
7.4% since SLE diagnosis. This frequency was similar to the
LUMINA cohorts (7%)13 despite the fact that our patients were
older and were followed-up for much longer periods. On the
other hand, compared with other European4,24 and Ameri-
can6,7,23,25 cohorts, the frequencies of which ranged from
9.8% to 19.0%, the prevalence in our cohort was much lower.
Although retrospective studies might underestimate the fre-
quency of events, some of these differences are likely due to
varying definitions of CV events and observation times, our
prevalence nonetheless remained relatively low. This low fre-
quency of CV events occurred even though our patients pre-
sented a high frequency of traditional risk factors, particularly
diabetes mellitus and smoking. This phenomenon has pre-
viously been observed in a non-SLE Spanish general popu-
lation.26 The ‘‘Spanish paradox’’ is a phenomenon observed
Medicine  Volume 94, Number 29, July 2015also in some other Mediterranean countries by which the CV
morbidity and mortality levels are dissociated from their CV
risk factors.26 Like other groups, we have observed a higher
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Cardiovascular Events in RELESSER-TRANS Patients That Occurred Since SLE Diagnosis as a Function of Demographic,
Clinical, and Treatment Characteristics
Variables
Cardiovascular Events
All SLE Patients
(N¼ 3649) P ValueYes (N¼ 269) No (N¼ 3380)
Demographic features
Sex: male, n (%) 37 (13.8) 316 (9.4) 353 (9.7) 0.018
Ethnicity: 0.031
Caucasian (European ancestry), n (%) 256 (97.3) 3044 (92.8) 3300 (90.4)
Amerindian Caucasians, n (%) 5 (1.9) 180 (5.5) 185 (5.1)
Black Africans, n (%) 0 8 (0.2) 8 (0.2)
Asians, n (%) 2 (0.8) 19 (0.9) 21 (0.6)
Other ancestry, n (%) 0 29 (0.9) 29 (0.8)
Age at protocol, median (IQR), y 54.9 (43.2–66.1) 44.4 (35.7–56.5) 45.0 (35.7–56.5) <0.001
Age at disease onset, median (IQR), y 34.6 (23.6–46.7) 30.4 (22.3–41.1) 30.5 (22.4–41.6) 0.002
Age at disease diagnosis, median (IQR), y 37.3 (25.3–49.3) 32.6 (24.1–43.1) 32.8 (24.1–43.67) 0.001
Age at first cardiovascular event, mean (SD), y 48.6 (17.1) 45.2 (15.4) 47.9 (16.8) 0.125
Disease duration (last visit to onset SLE),
median (IQR), mo
212.0 (120.8–289.0) 144.3 (80.5–228.6) 148.9 (82.8–234.2) <0.001
Comorbidities and traditional risk factors, n (%)
Hypertension, n (%) 151 (56.6) 910 (27.1) 1061 (29.1) <0.001
Dyslipidemia, n (%) 159 (60.2) 941 (29.0) 1100 (30.1) <0.001
Smoking: ever, n (%) 121/255 (47.5) 1229/3033 (40.5) 1350/3280 (37.0) 0.032
Smoking status 0.053
Current smoker, n (%) 44 (17.3) 506 (16.7) 550 (15.1)
Former smoker, n (%) 77 (30.2) 723 (23.8) 800 (21.9)
Never smoker, n (%) 134 (52.5) 1804 (59.5) 1938 (53.1)
Diabetes mellitus, n (%) 42 /15.8) 137 (4.1) 179 (4.9) <0.001
Postmenopausal status, n (%) 120/199 (60.3) 966/2753 (35.1) 1086/2952 (29.8) <0.001
Family history of CVD, n (%) 34 (17.1) 397 (16.0) 431 (11.8) 0.683
Heart failure, n (%) 56 (21.3) 96 (2.9) 152 (4.2) <0.001
Cardiomyopathy, n (%) 8 (3.0) 17 (0.5) 25 (0.7) <0.001
Rhythm disorders, n (%) 32 (12.2) 118 (3.5) 150 (4.1) <0.001
Pulmonary embolism, n (%) 15 (5.6) 107 (3.2) 122 (3.3) 0.034
Charlson index, median (IQR) 4.0 (3.0–6.0) 1.0 (1.0–3.0) 2.0 (1.0–3.0) <0.001
SLE clinical features
SELENA-SLEDAI at protocol, median (IQR) 2.0 (0.0–4.0) 2.0 (0.0–4.0) 2.0 (0.0–4.0) 0.610
SLICC/ACR-DI, median (IQR) 3.0 (2.0–5.0) 0.0 (0.0–1.0) 1.0 (0.0–2.0) <0.001
Katz severity index, median (IQR) 3.0 (2.0–5.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) <0.001
Malar rash, ever, n (%) 144 (54.3) 1842 (55.2) 1986 (54.4) 0.783
Discoid rash, ever, n (%) 55 (20.9) 691 (20.9) 746 (20.4) 0.998
Photosensitivity, ever, n (%) 152 (57.6) 2005 (61.1) 2157 (59.1) 0.253
Oral ulcers, ever, n (%) 115 (43.7) 1521 (46.4) 1636 (44.8) 0.408
Arthritis, ever, n (%) 210 (78.7) 2599 (78.0) 2809 (77.0) 0.812
Deforming or erosive arthritisy, n (%) 40 (15.1) 322 (9.7) 362 (9.9) 0.005
Serositis, ever, n (%) 97 (36.2) 724 (21.9) 821 (22.5) <0.001
Renal disorder, ever, n (%) 119 (45.2) 1067 (32.8) 1186 (32.5) <0.001
Neurological disorder, ever, n (%) 53 (20.0) 252 (7.6) 305 (8.4) <0.001
Valvular dysfunction (BILAG), n (%) 36 (14.1) 86 (2.7) 122 (3.3) <0.001
Valvular diseasey, n (%) 57 (21.5) 162 (4.9) 219 (6.0) <0.001
Raynaud phenomenon, ever, n (%) 109 (42.6) 1087 (33.3) 1196 (32.8) 0.003
Hematological disorder, ever, n (%) 220 (81.8) 2719 (80.8) 2939 (80.5) 0.678
Antiphospholipid syndrome, n (%) 97 (36.6) 405 (12.1) 502 (13.8) <0.001
Anti-dsDNA, n (%) 208 (78.8) 2406 (73.0) 2614 (71.6) 0.042
Low complement, n (%) 216 (83.7) 2567 (77.4) 2783 (76.3) 0.019
Anti-Sm positive, n (%) 56 (21.8) 676 (21.1) 732 (20.1) 0.798
Anti-Ro positive, n (%) 89 (34.4) 1306 (39.8) 1395 (38.2) 0.082
Anti-La positive, n (%) 42 (16.1) 643 (19.6) 685 (18.8) 0.162
Anti-RNP positive, n (%) 67 (25.8) 815 (25.0) 882 (24.2) 0.787
Antiphospholipid antibody positive, whatever, n (%) 137 (53.7) 1232 (39.0) 1369 (37.5) <0.001
Treatments
Antiplatelet drugs: ever, n (%) 151 (64.5) 940 (34.8) 1091 (29.9) <0.001
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Variables
Cardiovascular Events
All SLE Patients
(N¼ 3649) P ValueYes (N¼ 269) No (N¼ 3380)
Dicoumarin drugs: ever, n (%) 113 (43.5) 381 (12.0) 494 (13.5) <0.001
Statin drugs: ever, n (%) 149 (58.7) 694 (22.7) 843 (23.1) <0.001
NSAIDs: ever, n (%) 176 (67.4) 2284 (72.7) 2460 (67.4) 0.067
Antimalarial drugs: ever, n (%) 195 (75.6) 2683 (83.9) 2878 (78.9) 0.001
Glucocorticoids: ever, n (%) 252 (95.5) 2840 (88.4) 3092 (84.7) <0.001
High dose of glucocorticoids (>30mg/d): ever, n (%) 108 (44.4%) 686 (25.7) 794 (21,8) <0.001
Methotrexate: ever, n (%) 46 (17.6) 530 (16.6) 576 (15.8) 0.669
Azathioprine: ever, n (%) 124 (47.7) 1016 (31.9) 1139 (31.2) <0.001
Mycophenolate mofetil/mycophenolic acid: ever, n (%) 58 (22.2) 464 (14.6) 522 (14.3) 0.001
Cyclophosphamide: ever, n (%) 86 (33.2) 690 (21.6) 775 (21.2) <0.001
Rituximab, n (%) 26 (9.9) 200 (6.3) 226 (6.2) 0.022
Refractory SLE, n (%) 98 (36.4) 799 (23.6) 897 (24.6) <0.001
BILAG¼British Isles Lupus Assessment Group, CVD¼ cardiovascular disease, IQR¼ interquartile range, NSAIDs¼ nonsteroidal anti-inflam-
matory drugs, SD¼ standard deviation, SELENA-SLEDAI¼Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus
Erythematosus Disease Activity Index, SLE¼ systemic lupus erythematosus, SLICC/ACR-DI¼Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index, SLICC¼Systemic Lupus International Collaborating Clinics.
Ferna´ndez-Nebro et al Medicine  Volume 94, Number 29, July 2015frequency of cerebrovascular events compared with coronary or
peripheral artery diseases.9,13,23,27
Although men had a higher CV risk than the women in the
univariate analysis, this association was not confirmed in the
multivariate models. This is due to the fact that CV risk factors
promote atherosclerosis in both the sexes. Moreover, as has

From the last visit to diagnosis of SLE.
y SLICC/ACR damage index definition.been mentioned earlier, our patients presented a high frequency
of both diabetes mellitus and smoking, 2 CV risk factors that
have a greater impact on women than men.28,29
TABLE 4. Predictor of Cardiovascular Events That Occurred
Since Systemic Lupus Erythematosus Diagnosis in RELESSER
Patients By Multiple Logistic Regression Analysis
Independent Variable

OR 95% CI P Value
Age at protocol, y 1.03 1.02–1.04 <0.001
Hypertension 1.71 1.20–2.44 0.003
Smoking: ever 1.48 1.06–2.07 0.020
Diabetes mellitus 2.22 1.32–3.74 0.003
Dyslipidemia 2.18 1.54–3.09 <0.001
Serositis: ever 1.54 1.09–2.18 0.015
Neuropsychiatric lupus:
ever
2.42 1.56–3.75 <0.001
Valvular dysfunction
(BILAG definition)
2.44 1.34–4.26 0.002
Low complement 1.81 1.12–2.93 0.016
Antiphospholipid antibody
positivey, whatever
1.57 1.13–2.17 0.007
Azathioprine: ever 1.47 1.04–2.07 0.028
R2 Nagelkerke¼ 0.201. BILAG¼British Isles Lupus Assessment
Group, CI¼ confidence interval, OR¼ odds ratio.
Factors included in the model were age, sex, disease duration,
hypertension, dyslipidemia, smoking, diabetes mellitus, serositis, renal
disorder, neurological disorder, valvular dysfunction, Raynaud phenom-
enon, anti-dsDNA, low complement, antiphospholipid antibody
positive, nonsteroidal anti-inflammatory drugs, antimalarials, glucocor-
ticoids, methotrexate, and azathioprine.
yAccording to the revised Sidney laboratory criteria.
6 | www.md-journal.comAge contributes significantly to the development of ath-
erosclerosis both in SLE patients and in the general population.
Consistent with the previous reports,4,9,11,13,23,27 we found that
the age was associated with CVD in the multivariate analysis.
In fact, age increased the risk of CV events by 3% for each
yearly increase in age. This figure might be somewhat higher
than that observed in the general population (those between 40
and 50 years).30 Furthermore, the majority of our patients were
about 49 years old when they suffered their first CV event,
whereas in the non-SLE Spanish population this occurred at
age 60.31
Diabetes, hypertension, smoking, and dyslipidemia were
all independently associated with CV events in this study.
Dyslipidemia (treated or not treated) has been associated with
up to a 2-fold increased risk of CV events in SLE patients.7,32–34
Although these factors are strongly predictive of CVD in the
general population, the results are less uniform in SLE patients.
In fact, this is the first study to demonstrate that diabetes
mellitus is associated with CV events in SLE. Unlike our
own, none of the studies identified in a recent systematic review
found that diabetes or its treatment was an independent risk
factor for CVD among SLE patients.3
On the contrary, smoking increases the risk for developing
SLE35 and has been associated with a risk of CV events in SLE
patients in some studies.13,23,36–39 Other groups, however, have
not confirmed this association.4,9,24,32 As our study is cross-
sectional in nature, it cannot prove causality, only association.
Thus, we decided to group smoking exposure as a single item
(ie, past and active smoker) in the multivariate analyses. Fre-
quently, patients with a high CV risk profile are more likely to
quit smoking on their own initiative or when encouraged by
their doctors or family. This is particularly true after a CV event
has occurred. In fact, we have observed that the proportion of
former smokers was significantly higher among those patients
who suffered a CV event after SLE diagnosis. All these reasons
suggest that in this kind of study, smokers have an otherwise
better risk profile than nonsmokers, for example, they tend to be
significantly younger and have a lower incidence of diabetes,
hypertension, previous infarction, and severe coronary disease
than nonsmokers.40 Similarly, other groups have reported an
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
association between hypertension and CV events,32–34,41,42
particularly with strokes in SLE patients.33
Several characteristics related to SLE or treatments of it
have been identified in our study that might partly explain the
high risk of CV events in this patient population. These factors
include serositis, low complement, neuropsychiatric lupus,
valvular dysfunction (SLICC/ACR DI definition), antiphospho-
lipid antibodies, and azathioprine but not SLENA-SLEDAI
index at the last visit. Our results confirm those obtained by
most, but not all, other groups.7,33,34 Although a relationship
appears to exist between lupus activity and a higher frequency
of CVD,43 we think that an isolated measurement of SELENA-
SLEDAI is not enough to identify patients at risk. Thus, our
patients present a higher frequency of clinical and laboratory
manifestations related to disease activity, such as serositis, low
complement, and neuropsychiatric lupus. In fact, neuropsychia-
tric lupus has been identified in a few studies as a strong
predictor of CV events.23,37 In this sense, Urowitz et al37
suggested that neurolupus might increase the risk of CV events,
both coronary and noncoronary, almost 4-fold.
On the contrary, valvulopathy in SLE can be caused by
activity or damage and is a known source of cerebral emboli
causing transient ischemic attacks and strokes. In our study, both
definitions of valvulopathy (activity and damage)were identified
as risk factors for CV events in general. However, valvulopathy
was not associated with strokes alone in our SLE patients.
Interestingly, our SLE patients who were positive for
antiphospholipid antibodies had a 57% greater risk of suffering
a CV event. As antiphospholipid syndrome is characterized by
recurrent arterial thrombosis, including ictus and myocardial
infarction, it is possible that not all of the vascular events
recorded in our study have an atherosclerotic origin. However,
it is often impossible to accurately attribute the etiology of such
events. Furthermore, these antibodies appear to be positively
associated with a history of smoking in patients with a CV event
history, particularly in former smokers.44 Indeed, this might
represent a second-hit triggering of CV events in patients with
preexisting atherosclerosis.13,38,39,43 Finally, antiphospholipid
antibodies might play a role in the development of atheroscle-
rosis via several mechanisms, such as the proinflammatory
activity they directly or indirectly exert on endothelial cells,45
or by enhancing the lipid peroxidation of lipoproteins46 or
reducing paraoxonase activity.47
Although there is good evidence that hydroxychloroquine
prevents lupus flares and increases long-term survival in
patients with SLE, it is less clear that it reduces the risk of
CV events.48 Our univariate analysis suggests that it has a
lowering effect on the risk of CV events risk, although this
was not the case in the multivariate analysis.
Glucocorticoids have a complex effect on CV risk because
of their ability to reduce inflammatory activity. However, they
remain associated with hypertension, hyperglycemia, and central
obesity.49 In our multivariate analysis, glucocorticoid use had no
association with CVD. Only a few authors have demonstrated an
association between glucocorticoids and CV events in SLE
patients,32,34 probably owing to differences in the definitions
of variables (eg, time of use, cumulative doses, and others).7,50 By
contrast, azathioprine increased the risk of vascular events in 47%
of our patients. Azathioprine correlated with more severe SLE
and several studies have confirmed this association.41,51
Our study also has, however, several limitations, the main
Medicine  Volume 94, Number 29, July 2015one being its retrospective design. This could affect SLICC/
ACR DI calculations and lead to an underestimation of
the frequency of valvular dysfunction or rhythm disorder.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Nevertheless, good agreements exist between prospective
and retrospective evaluation SLICC/ACR DI scores52 and
SLEDAI.53 However, this limitation may be overcome in
the RELESSER-PROS study that is now ongoing. Another
important limitation concerns the etiologic attribution of
events. CV events in SLE, particularly heart failure and rhythm
disorders, can be the result of several causes, such as lupus
activity, fluid overload, anemia, and others. Therefore, to
reduce this limitation, none of these variables were counted
as CV events. Nevertheless, in daily clinical practice, it is often
not possible to establish the exact etiology of some CV event
because of the concurrence of 1 pathogenic mechanisms in
the same patient. A further limitation of our study was that we
did not include important traditional risk factors, such as
obesity and sedentary lifestyle. Furthermore, we did not con-
sider 2 subgroups of diabetes (ie, types 1 and 2 diabetes), which
in the context of SLE could be totally different. Although the
prevalence of type 1 diabetes in SLE is unknown, it should be
quite low,54 and thus its influence minimal. Finally, the
strengths of the present study include the large sample size,
the generalized use of validated indexes, and the mandatory
clinical training of the coinvestigator.
CONCLUSION
To conclude, we have confirmed that SLE patients suffer a
high prevalence of premature CVD. As with the Spanish general
population, this prevalence was lower than that detected in SLE
patients from either Northern Europe or Canada, despite the fact
that our patients had higher prevalence of both diabetes and
smoking. Our study not only emphasizes the importance of
recognizing the CV risk factors in these patients, but also
shows—for the first time—an association between diabetes
and CV events in SLE patients. However, the latter finding
needs to be verified via specifically designed studies. The main
SLE manifestations associated with CV events were serositis,
neuropsychiatric lupus, valvular dysfunction, low complement,
positive antiphospholipid antibodies, and azathioprine.
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